Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · Real-Time Price · USD
2.410
+0.070 (2.99%)
Nov 21, 2024, 2:38 PM EST - Market open
Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system.
In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs.
Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology, Inc.
Country | United States |
Founded | 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 167 |
CEO | Sujal Patel |
Contact Details
Address: 2701 Eastlake Avenue East Seattle, Washington 98102 United States | |
Phone | 206 333 2001 |
Website | nautilus.bio |
Stock Details
Ticker Symbol | NAUT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001808805 |
CUSIP Number | 63909J108 |
ISIN Number | US63909J1088 |
Employer ID | 98-1541723 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Sujal M. Patel | Co-Founder, Chief Executive Officer, President, Secretary and Director |
Dr. Parag Mallick Ph.D. | Co-Founder, Chief Scientist and Director |
Anna Mowry | Chief Financial Officer and Treasurer |
Matthew B. Murphy ESQ. | General Counsel |
Chris Blessington | Vice President of Corporate Marketing and Communications |
Kentaro Suzuki | Chief Marketing Officer |
Gwen E. Weld | Chief People Officer |
Nick A. Nelson | Chief Business Officer and Senior Vice President of Business Development |
Dr. Subra Sankar Ph.D. | Senior Vice President of Product Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 19, 2024 | 144 | Filing |
Nov 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 12, 2024 | 144 | Filing |
Nov 8, 2024 | 144 | Filing |
Nov 7, 2024 | 144 | Filing |
Oct 29, 2024 | 10-Q | Quarterly Report |
Oct 29, 2024 | 8-K | Current Report |
Sep 23, 2024 | 144 | Filing |
Sep 17, 2024 | 144 | Filing |
Jul 30, 2024 | 10-Q | Quarterly Report |